Pediatric Anaphylaxis: Recognition, IM Epinephrine Dosing, and Discharge Planning

Pediatrics · Allergy Emergency

Pediatric Anaphylaxis: Recognition, IM Epinephrine Dosing, and Discharge Planning

Bedside framework for recognizing pediatric anaphylaxis using NIAID/EAACI criteria, delivering weight-based IM epinephrine without delay, managing biphasic reactions, prescribing auto-injectors, and applying the LEAP-era food allergy framework.

By gomdori, MD Reading time: 17 min Updated 2026-07-20

Executive Summary

Pediatric anaphylaxis is a rapidly evolving, IgE-mediated systemic hypersensitivity reaction that is under-recognized, under-treated with epinephrine, and over-treated with antihistamines and steroids. Diagnosis uses NIAID/EAACI 2020 criteria: any acute illness involving skin/mucosa plus respiratory or cardiovascular compromise, or two organ systems after a likely allergen exposure, or hypotension after a known allergen. The single life-saving intervention is intramuscular epinephrine 0.01 mg/kg of the 1 mg/mL (1:1000) solution into the anterolateral thigh, with a maximum single dose of 0.5 mg, repeatable every 5–15 minutes. Auto-injector dosing follows weight bands: 0.15 mg for 7.5–25 kg (0.1 mg for 7.5 to <15 kg as an alternative where available, per the Auvi-Q label) and 0.3 mg for ≥25 kg; below 7.5 kg no auto-injector is labeled, so draw up 0.01 mg/kg from 1 mg/mL. Adjunctive therapies (H1 antihistamines like cetirizine 0.25 mg/kg, H2 blockers like famotidine, corticosteroids, bronchodilators, IV fluids) treat residual symptoms but never substitute for epinephrine. Biphasic reactions occur in up to 20% of pediatric cases — observe asymptomatic patients 4–6 hours after a single uncomplicated dose, longer for severe presentations. Discharge requires two auto-injectors, a written anaphylaxis action plan, allergy referral, and family education. The LEAP and EAT trials transformed prevention: early introduction of peanut, egg, and other allergens in high-risk infants between 4–6 months reduces food allergy development by 70–80%.

~2%
Lifetime risk in children
85%
Cases triggered by food
5–20%
Biphasic reaction rate
<30%
Pre-hospital epinephrine use

S1. Pathophysiology and Recognition

Anaphylaxis is a clinical diagnosis. In children, the classic IgE-mediated mechanism dominates: allergen exposure cross-links IgE bound to FcεRI receptors on mast cells and basophils, triggering degranulation with release of histamine, tryptase, leukotrienes, prostaglandins, platelet-activating factor, cytokines, and chemokines within minutes. The result is multi-system smooth muscle contraction, vasodilation, increased vascular permeability, and mucus production, producing the characteristic combination of urticaria, angioedema, bronchospasm, hypotension, and gastrointestinal symptoms.

NIAID/EAACI 2020 Diagnostic Criteria

Anaphylaxis is highly likely when any one of the following three criteria is met:

CriterionRequired Features
Criterion 1
(most common)
Acute onset (minutes to hours) of illness with involvement of skin, mucosal tissue, or both (urticaria, pruritus, flushing, swollen lips/tongue/uvula) AND at least one of: (a) respiratory compromise (dyspnea, wheeze, stridor, hypoxemia), (b) reduced BP or end-organ dysfunction (hypotonia, syncope, incontinence)
Criterion 2Two or more of the following occurring rapidly after exposure to a likely allergen: (a) skin/mucosal involvement, (b) respiratory compromise, (c) reduced BP or end-organ dysfunction, (d) persistent GI symptoms (crampy pain, vomiting)
Criterion 3Reduced BP after exposure to a known allergen: pediatric hypotension defined as systolic BP <70 mmHg (1 mo–1 y), <70 + 2×age (1–10 y), <90 mmHg (11–17 y), or >30% drop from baseline

Pediatric Pitfall: Skin Findings May Be Absent

Skin manifestations are present in 80–90% of cases — but their absence does not rule out anaphylaxis. Up to 10–20% of fatal cases have no skin findings, especially in young children, infants on beta-blockers, or rapidly progressing reactions. Trust respiratory or cardiovascular signs even without urticaria, particularly after a known or likely exposure.

Symptom Recognition by Organ System

SystemCommon in ChildrenSevere / Red Flag
Skin / Mucosal (80–90%)Urticaria, pruritus, flushing, lip/tongue/face swelling, conjunctival injectionGeneralized urticaria with angioedema; periorbital swelling progressing to airway involvement
Respiratory (60–70%)Cough, wheeze, dyspnea, hoarseness, throat tightness, rhinorrheaStridor, severe wheeze, cyanosis, SpO&sub2; <92%, retractions, silent chest, voice change
Cardiovascular (10–30%)Tachycardia, dizziness, pallor, weak pulse, syncopeHypotension, bradycardia (late, ominous), shock, cardiac arrest
Gastrointestinal (30–45%)Crampy abdominal pain, nausea, vomiting, diarrheaPersistent severe vomiting; GI symptoms in food-triggered cases often herald systemic progression
NeurologicAnxiety, “feeling of impending doom”, irritability (preverbal child)Confusion, lethargy, seizure, loss of consciousness

Time Course of Anaphylaxis

Anaphylaxis Time Course Timeline showing initial reaction within 5-30 minutes, peak severity, resolution, and possible biphasic recurrence at 4-12 hours after the initial reaction resolves. 0 min 30 min 2 h 8 h 24 h Initial reaction (peak) Resolution Biphasic recurrence (5-20%)

Figure 1. Anaphylaxis time course — initial reaction peaks within 30 minutes, with possible biphasic recurrence 4–12 hours after symptoms resolve.

Pediatric Anaphylaxis — Hypersensitivity Mechanisms Gell and Coombs hypersensitivity classification Types I through IV with mechanisms and clinical examples Pediatric Anaphylaxis — Hypersensitivity Mechanisms Immunological mechanism, time course, and clinical examples Type I Immediate IgE-mediated IgE → Mast cell degranulation Onset: Minutes Anaphylaxis, Asthma, Urticaria Type II Cytotoxic IgG/IgM IgG/IgM + Complement/ADCC Onset: Hours AIHA, ITP, Goodpasture, Rh HDN Type III Immune Complex Ag-Ab complex → Complement Onset: 6–12h SLE, Post-strep GN, Serum sickness Type IV Delayed T-cell (DTH) Th1/CD8 → Macrophage activation Onset: 48–72h TB PPD, Contact dermatitis, Graft Type Key Cells/Abs Complement? Skin Test Treatment Basis Type I IgE, Mast, Basophil No Immediate wheal-flare Antihistamine, Epi, Omalizumab Type II IgG/IgM, NK, MAC Yes N/A Steroids, IVIG, Plasmapheresis Type III IgG complexes Yes Arthus (4–8h) Steroids, NSAIDs, Plasmapheresis Type IV CD4 Th1, CD8 Tc No PPD 48–72h induration Steroids, Calcineurin inhibitors
Pediatric Anaphylaxis — Hypersensitivity Mechanisms

S2. Acute Management: Epinephrine First

The single most important action in anaphylaxis is immediate intramuscular epinephrine. Delays in epinephrine administration are the strongest predictor of fatal outcomes. Antihistamines, steroids, and bronchodilators are adjuncts only.

Epinephrine: Dose, Route, Concentration

ParameterSpecification
Dose0.01 mg/kg IM (max single dose 0.5 mg in children, 0.5 mg in adults)
Concentration1 mg/mL (1:1000) — NOT the 0.1 mg/mL (1:10,000) used for cardiac arrest
SiteAnterolateral thigh (vastus lateralis) — fastest absorption; avoid deltoid in children
RepeatEvery 5–15 minutes if no response or symptom progression; up to 3 doses before considering IV infusion
IV indicationPersistent hypotension after 2–3 IM doses + IV fluids: epinephrine infusion 0.05–0.1 mcg/kg/min (titrate)

Volume to Draw Up (1:1000 Solution)

Weight (kg)Dose (mg)Volume of 1 mg/mL (mL)Auto-injector device
50.050.05 mLDraw up (no auto-injector labeled below 7.5 kg)
100.100.10 mL0.15 mg device
150.150.15 mL0.15 mg device
200.200.20 mL0.15 mg device (use 0.3 if >25 kg)
250.250.25 mL0.3 mg device
300.300.30 mL0.3 mg device
400.400.40 mL0.3 mg device
≥500.50 (max)0.50 mL0.3 mg or 0.5 mg device

Concurrent Resuscitation (Epinephrine in Parallel, Not in Series)

0 minIM epinephrine + call code
0–2 minPosition: supine, legs up (Trendelenburg) unless dyspneic
0–5 minO&sub2; high-flow + IV access ×2 large-bore
5–10 minNS bolus 20 mL/kg if hypotensive; repeat ×3
5–15 minRepeat IM epinephrine if no response
15+ minAdjuncts: H1, H2, steroid, bronchodilator, vasopressor if refractory

Adjunctive Therapies (Never First-Line)

DrugPediatric DoseRole
Cetirizine (H1)0.25 mg/kg PO/IV (max 10 mg)Relieves urticaria/itching only; preferred over diphenhydramine (less sedation, faster onset, IV form available)
Diphenhydramine (H1)1 mg/kg IV/IM/PO (max 50 mg)Older H1; sedation can mask CNS deterioration; often given but not preferred
Famotidine (H2)0.25 mg/kg IV (max 20 mg)Adjunct to H1 for urticaria/flushing; modest evidence
Methylprednisolone1–2 mg/kg IV (max 125 mg)Often given but recent evidence (2020 Cochrane, 2024 cohort studies) shows no proven prevention of biphasic reactions; use selectively for severe asthma component
Albuterol nebulized2.5 mg neb (5 mg if >30 kg)For persistent bronchospasm after epinephrine
Glucagon IV20–30 mcg/kg IV bolus, then 5–15 mcg/min infusionIf on beta-blocker with refractory shock
Vasopressors (norepi)0.05–0.5 mcg/kg/min IVRefractory hypotension after IV fluids + repeated epinephrine; use with PICU support
Common Fatal Error: Delaying Epinephrine While Giving Antihistamines The most consistently identified contributor to fatal pediatric anaphylaxis is delayed epinephrine — usually because clinicians (or schools/parents) reach for diphenhydramine first, then “wait and see.” Epinephrine should be given within 5 minutes of recognized anaphylaxis. If you’re considering giving an antihistamine, you’ve already met criteria for epinephrine. There is no “anaphylaxis-mild” diagnosis that justifies skipping epinephrine — IM epinephrine has an extremely safe profile in children even when symptoms turn out to be milder than feared.

S3. Biphasic Reactions and Observation

A biphasic anaphylactic reaction is a recurrence of symptoms 1–72 hours (typically 4–12 hours) after the initial episode resolves, without re-exposure to the trigger. Reported pediatric incidence ranges from 5% to 20% depending on definition; clinically significant biphasic reactions requiring additional epinephrine occur in roughly 5%.

Predictors of Biphasic Reaction

  • Severity of initial reaction (hypotension, hypoxia, throat involvement)
  • Delayed epinephrine administration (each 30-minute delay increases biphasic risk)
  • Need for >1 dose of epinephrine
  • Wide pulse pressure or tachycardia at discharge
  • Unknown trigger (cannot avoid re-exposure)
  • History of biphasic reaction

Observation Periods (AAP / EAACI Consensus)

Clinical scenarioRecommended observation
Mild–moderate reaction, single epinephrine dose, complete resolution, low-risk trigger known4–6 hours post symptom resolution, then discharge with action plan
Required >1 epinephrine dose, severe respiratory or CV symptoms, or unknown trigger12–24 hours observation; consider admission
Hypotension requiring fluids/vasopressors, intubation, refractory bronchospasmPICU admission; minimum 24-hour observation post-resolution
History of biphasic reaction or known severe asthmaExtend observation to at least 12–24 hours

What to Watch For During Observation

  • Recurrence of skin findings (urticaria, flushing, lip swelling)
  • Respiratory deterioration (wheeze, stridor, increased work of breathing)
  • Cardiovascular changes (tachycardia, hypotension, syncope)
  • GI symptoms (vomiting, abdominal pain)
  • Vital signs every 15–30 minutes initially, then hourly if stable
Pediatric Anaphylaxis — Procedure Steps Surgical stepper: Pediatric Anaphylaxis — Procedure Steps Pediatric Anaphylaxis — Procedure Steps 1 IM epinephrine — STAT 0.01 mg/kg (1:1000) IM in vastus lateralis; max 0.5 mg (0.01 mg/kg, 1:1000); repeat q5–15 min 2 Position + airway Supine with legs elevated; high-flow O2; intubation if airway compromise 3 IV access + fluids Large-bore IV; NS 20 mL/kg bolus, repeat as needed; up to 60 mL/kg 4 Adjuncts H1 blocker: cetirizine 5-10mg; H2 blocker: famotidine; methylpred 1-2 mg/kg IV; albuterol for 5 Refractory IV epi infusion 0.1-1 mcg/kg/min; glucagon 20-30 mcg/kg if β-blocker; vasopressors 6 Discharge Observe ≥4-8h; epi auto-injector x2 at school + home; allergist referral; written action plan; schoo
Pediatric Anaphylaxis — Procedure Steps

S4. Common Triggers and Mimics

Pediatric Triggers by Age and Frequency

Age groupMost common triggersNotes
Infants (<1 y)Cow’s milk, egg, peanut, soy, wheatOften presents as feeding-associated reactions; consider FPIES as a differential (delayed, profuse vomiting)
Toddlers / preschool (1–5 y)Peanut, tree nuts, egg, milk, sesameSesame added as 9th major US allergen (FASTER Act 2021); look for “vegan” or unlabeled bakery items
School age (6–12 y)Peanut, tree nuts, fish, shellfish, sesamePeanut and tree nut allergies often persist into adulthood
Adolescents (13–18 y)Peanut, tree nuts, shellfish, fish, sesame, exercise-induced (food-dependent)High-risk group for fatal anaphylaxis (delayed self-treatment, asthma comorbidity, restaurant exposures, alcohol disinhibition)
All agesHymenoptera stings, drugs (beta-lactams, NSAIDs), latex, vaccines (rare)Drug-induced anaphylaxis often biphasic; latex high-risk in spina bifida patients

The “Top 9” Pediatric Food Allergens

Peanut, tree nuts, milk, egg, wheat, soy, fish, shellfish, and sesame account for >90% of pediatric food anaphylaxis. Sesame was added to the US labeling law in January 2023 (FASTER Act).

Differential Diagnosis

MimicKey distinguishing features
Vasovagal syncopeBradycardia (not tachycardia), pallor without urticaria, prompt recovery when supine
Acute asthma exacerbationWheezing without urticaria/angioedema, no clear allergen exposure (though severe asthma can coexist with anaphylaxis)
Foreign body aspirationSudden onset, choking, focal wheeze/stridor, no skin findings; consider in toddlers
Panic attack / hyperventilationParesthesias, tetany, normal exam findings, no urticaria
Vocal cord dysfunctionInspiratory stridor without bronchospasm; flat flow-volume loop on inspiratory limb
Scombroid poisoningMimics anaphylaxis (flushing, urticaria, GI), but caused by histamine in spoiled fish (tuna, mahi-mahi); responds to antihistamines
FPIES (food protein–induced enterocolitis)Profuse vomiting + lethargy 1–4h after food; no urticaria, no respiratory distress, often cow’s milk/soy/oats/rice in infants
Mast cell activation syndrome (MCAS)Recurrent multi-system symptoms with elevated tryptase or other mediators; consider in repeated unexplained anaphylaxis
Idiopathic anaphylaxisNo identifiable trigger after thorough workup; treat episodes the same; consider prophylactic therapy if recurrent

Tryptase Testing (When Diagnosis Unclear)

Serum tryptase peaks 1–2 hours after symptom onset and returns to baseline by 6–8 hours. A level >11.4 ng/mL (or >1.2 × baseline + 2 ng/mL) supports mast cell activation. Useful when the diagnosis is unclear, when anaphylaxis is fatal/peri-arrest, or when MCAS is suspected. Order acute (within 4 hours) and a baseline level >24 hours after recovery.

S5. Discharge Planning, Action Plan, Auto-Injector Prescription

Discharge after anaphylaxis is a critical teaching opportunity that can prevent future fatalities. Every patient with anaphylaxis should leave with five things: epinephrine prescription, demonstration of use, written action plan, allergy referral, and clear “when to return” criteria.

Auto-Injector Prescription

Patient weightAuto-injector doseDevices available
<7.5 kg0.01 mg/kg drawn upNo auto-injector labeled below 7.5 kg; use 1 mg/mL
7.5 to <15 kg (alternative)0.1 mgAuvi-Q 0.1 mg (US, labeled 7.5 to <15 kg); not all countries
7.5–25 kg0.15 mgEpiPen Jr, Auvi-Q 0.15, Adrenaclick Jr
≥25 kg0.3 mgEpiPen, Auvi-Q 0.3, Adrenaclick
≥50 kg (some regions)0.5 mgEmerade 0.5 mg (UK/Europe)
Always Prescribe Two Devices Auto-injectors can fail (clogged needle, accidental discharge into thumb), and a second dose may be needed in 5–15 minutes if symptoms persist or recur. Insurance typically covers two devices per prescription. Consider three devices for adolescents at high-risk school environments or families with split custody.

Anaphylaxis Action Plan (Written, Pictorial)

Provide a written action plan customized to the child, signed by a clinician, copies for parents, school nurse, and caregivers. Standard templates: AAAAI, Food Allergy Research & Education (FARE), Anaphylaxis Canada. Plan should include:

  • Child’s name, photo, weight, allergens, asthma comorbidity
  • Mild symptom list with H1 antihistamine dose (cetirizine)
  • Severe symptom list with epinephrine instruction (auto-injector dose, anterolateral thigh, through clothing)
  • “After epinephrine: call 911” instruction, position supine with legs raised
  • Auto-injector device images (EpiPen, Auvi-Q) with use steps
  • Emergency contacts and prescribing physician info

Discharge Education Checklist

  • Demonstrate auto-injector use on a trainer device; have parent/child return-demonstrate
  • Review trigger identification and avoidance (food labels, restaurant strategies, “may contain” warnings)
  • Always carry two auto-injectors in original packaging at body temperature (extreme heat/cold inactivates)
  • Check expiration date — set calendar reminder; epinephrine expires 12–18 months from manufacture
  • Use auto-injector even if uncertain — risk of withholding far exceeds risk of unnecessary dose
  • Always call 911 after epinephrine use for transport and observation, even if feeling better
  • Wear medical ID bracelet (MedicAlert)
  • Allergy follow-up within 4 weeks for confirmatory testing and management plan
  • School notification: action plan to nurse, teacher, cafeteria; some schools require physician-signed forms
When to Refer (Allergy/Immunology) • Every patient with confirmed anaphylaxis — referral within 4 weeks for skin prick testing, specific IgE, and management plan. • Recurrent anaphylaxis without identified trigger — workup for MCAS, idiopathic anaphylaxis, hereditary alpha-tryptasemia. • Hymenoptera sting anaphylaxis — venom immunotherapy reduces future fatal sting risk by >95%. • Drug-induced anaphylaxis — supervised drug challenge or desensitization for unavoidable medications (penicillin, chemotherapy). • High-risk infants (severe eczema, egg allergy) for early peanut introduction guidance per LEAP framework.

S6. Long-term Follow-up and the LEAP/EAT Era

The 2015 LEAP trial transformed pediatric food allergy prevention by demonstrating that early peanut introduction in high-risk infants reduces peanut allergy by ~80% compared with avoidance. The 2016 EAT trial extended this concept to multiple allergens. NIAID 2017 and AAP 2019 guidelines now recommend early introduction across the spectrum of risk.

LEAP Trial Summary

  • 640 high-risk infants (severe eczema, egg allergy, or both) age 4–11 months randomized to early peanut introduction or strict avoidance until age 5
  • Early introduction group: peanut allergy at age 5 was 1.9% (avoidance group: 13.7%), an 81% relative risk reduction
  • LEAP-On: tolerance persisted after 12-month avoidance period in early-introduction group

NIAID 2017 Peanut Introduction Guidance

Risk groupRecommendationPre-introduction testing
High risk: severe eczema and/or egg allergyIntroduce age-appropriate peanut foods at 4–6 monthsStrongly consider peanut-specific IgE or skin prick test before; if SPT 0–2 mm or IgE <0.35 introduce at home; if larger, supervised feeding with allergist
Moderate risk: mild–moderate eczemaIntroduce around 6 months as part of solid foodsTesting not required
Low risk: no eczema, no other food allergyIntroduce at age-appropriate time (around 6 months) with family preferencesNo testing

How to Introduce Peanut Safely at Home

  • Wait until baby has tolerated other solid foods (often rice cereal, pureed vegetables/fruits)
  • Forms suitable for infants: smooth peanut butter thinned with warm water/breast milk/formula, peanut puff snacks (e.g., Bamba), peanut powder mixed into purees
  • Never give whole peanuts or chunks of peanut butter (choking hazard until age 4)
  • Start with small amount (¼ teaspoon) and observe 10–15 minutes; increase if no reaction
  • Continue regular peanut consumption ≥2–3 times/week
  • If reaction: stop, give H1 if mild urticaria; epinephrine if any respiratory or systemic features

Other Foods (EAT Trial Framework)

The EAT trial showed early introduction (age 3 months) of multiple allergens (peanut, egg, milk, sesame, fish, wheat) into the breastfed infant diet reduced food allergy by ~67% in the per-protocol analysis. AAP 2019 supports introduction of allergenic foods around 4–6 months alongside other complementary foods. Egg should be cooked thoroughly (no raw or undercooked egg). Sesame products (tahini, hummus) introduced as smooth pastes mixed with foods.

Long-term Allergy Outcomes by Trigger

AllergenResolution rate by school age
Cow’s milk~80% by age 16
Egg~70% by age 16
Wheat~65% by age 12
Soy~65% by age 10
Peanut~20% (most persist into adulthood)
Tree nuts~10% (most persist)
Fish / shellfishMost persist into adulthood

Oral Immunotherapy (OIT) for Peanut Allergy

Palforzia (peanut oral immunotherapy) was FDA-approved in 2020 for ages 4–17 with confirmed peanut allergy. Achieves “bite-proof” protection (typically tolerating 600 mg cumulative peanut protein, ~2 peanuts) in 67% by 6–12 months. Side effects: mild GI symptoms, eosinophilic esophagitis (rare), need for daily dosing. Does not “cure” allergy — patients must continue daily maintenance and carry epinephrine.

S7. Pearls, Pitfalls, and FAQ

Pearl: Give epinephrine first, label the diagnosis later There is no penalty for giving IM epinephrine to a child you suspect has anaphylaxis but turns out to have a less severe allergic reaction. The risk of withholding far exceeds the risk of unnecessary dose. Tell parents and trainees: “If you’re considering an antihistamine and the child has any respiratory or cardiovascular feature, the antihistamine is the wrong drug — give epinephrine, then the antihistamine.” This single rule saves lives in real-world practice where time-to-epinephrine drives outcomes.
Pitfall: Sending a child home without an auto-injector after “mild” food reaction A child who develops urticaria + vomiting after eating peanut butter has met anaphylaxis criteria (skin + GI in a likely-allergen exposure under criterion 2). Even if symptoms resolved spontaneously, the child needs two auto-injectors, an action plan, and allergy follow-up — because the next reaction is unpredictable in severity. Epinephrine prescription is not optional after any anaphylaxis episode regardless of treatment given in ED.
Pearl: Cetirizine is preferred over diphenhydramine for adjunct H1 blockade Diphenhydramine has been the historical default but has slow onset (60+ min PO), causes sedation that can mask CNS deterioration, has anticholinergic effects, and crosses the blood-brain barrier. Cetirizine (oral) or its IV form has faster onset (~30 min), no sedation, and is non-inferior for urticaria control. AAAAI now recommends cetirizine 0.25 mg/kg as the preferred adjunct H1 in pediatric anaphylaxis.
Pitfall: Asking “is the child hypotensive?” to diagnose anaphylaxis Children compensate for shock for a long time before BP drops — they are tachycardic, mottled, and pale long before their measured BP becomes abnormal. Once a pediatric BP drops in anaphylaxis, the patient is in late-stage shock. Use criteria 1 and 2 (skin + respiratory or skin + 2 organ systems) for early recognition; do not wait for hypotension. In a teen, postural dizziness or transient syncope after a known allergen exposure is criterion 3.

Frequently Asked Questions

What is the correct IM epinephrine dose for a 20 kg child in anaphylaxis?
For a 20 kg child, give 0.2 mg of 1 mg/mL (1:1000) epinephrine intramuscularly into the anterolateral thigh, which equals 0.2 mL of the 1:1000 solution. The general dose is 0.01 mg/kg with a maximum single dose of 0.5 mg in children. If using an auto-injector, a child weighing 7.5 to 25 kg should receive a 0.15 mg device, and ≥25 kg should receive a 0.3 mg device.
How long should I observe a child after a single dose of epinephrine for anaphylaxis?
Observe for at least 4 to 6 hours after symptom resolution if response to a single epinephrine dose is rapid and complete. Extend observation to 12 to 24 hours if the patient required more than one dose, had hypotension, severe respiratory compromise, or a known biphasic risk factor; very prolonged or severe initial reactions warrant overnight inpatient monitoring.
Are antihistamines and steroids first-line treatment for anaphylaxis?
No. Intramuscular epinephrine is the only first-line treatment that addresses airway, breathing, and circulation. H1 antihistamines such as cetirizine relieve only urticaria and itching, H2 antihistamines such as famotidine are adjuncts, and corticosteroids show no proven benefit in preventing biphasic reactions in current evidence; their use should never delay or substitute for epinephrine.
How do I prescribe and educate about an epinephrine auto-injector at discharge?
Prescribe two auto-injectors (one set may fail or a second dose may be needed in 5 to 15 minutes) at the appropriate weight band: 0.15 mg for 7.5 to 25 kg (0.1 mg for 7.5 to under 15 kg as an alternative if available) and 0.3 mg for 25 kg or more; below 7.5 kg no auto-injector is labeled, so use weight-based dosing (0.01 mg/kg) drawn up from 1 mg/mL. Demonstrate use on a trainer device, provide a written anaphylaxis action plan, instruct the family to call emergency services after every use, and arrange allergy follow-up within 4 weeks.
When should I introduce peanut to an infant at high risk of peanut allergy?
For infants at high risk (severe eczema or egg allergy), the LEAP trial supports introducing age-appropriate peanut-containing food between 4 and 6 months of age, ideally after evaluation by an allergist (skin prick testing or peanut-specific IgE) when feasible. Early introduction reduces peanut allergy development by approximately 80% compared with avoidance.

Practice Insights: Lessons from Pediatric Anaphylaxis in ED and Allergy Clinic

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Waiting for wheeze or hypotension before giving epinephrine misreads an anaphylaxis diagnosis that was already made at the door, which explains why the failures in this disease are almost never about diagnosis at the bedside — they are about epinephrine delay before arrival, the second-dose hesitation in the emergency department, the discharge planning that omits the spare auto-injector, and the LEAP-era introduction window that primary care still treats as “delay until age 3.” In experienced practice the four patterns experienced clinicians track most carefully are the antihistamine-first reflex that delays epinephrine, the underdosing or wrong-site administration that compromises absorption, the biphasic-reaction observation window that has shifted shorter for mild cases, and the early-introduction conversation that prevents future anaphylaxis entirely in high-risk infants.

Pediatric Anaphylaxis: IM Epinephrine Dosing, Second-Dose Triggers, Observation Tiers, and LEAP Early Introduction Four-panel matrix showing weight-based IM epinephrine dosing, second-dose criteria, biphasic observation tiers, and LEAP-era early peanut introduction window. Pediatric Anaphylaxis: Four Bedside Anchors at Diagnosis Through Follow-Up ① IM Epinephrine — Weight-Based Weight Dose Auto-injector < 7.5 kg (infant) 0.01 mg/kg IM Draw up 1 mg/mL 7.5–25 kg 0.15 mg IM EpiPen Jr / Auvi-Q 0.15 > 25 kg 0.3 mg IM EpiPen / Auvi-Q 0.3 Site: vastus lateralis (mid-anterolateral thigh) ▸ NEVER deltoid, NEVER subcutaneous ▸ Vastus has highest perfusion → fastest absorption ▸ Through clothing if needed in field Volume formula: 0.01 mg/kg of 1:1000 IM ② Second-Dose Triggers (~40% need ≥ 2) Repeat IM epi at 5–15 min if: ▸ Persistent or worsening respiratory symptoms ▸ Persistent hypotension after first dose + fluids ▸ Progression to cardiovascular collapse Adjuncts (NOT primary): ▸ IV fluids 20 mL/kg NS, repeat ×2–3 if hypotensive ▸ Salbutamol nebulizer for bronchospasm ▸ H1 + H2 antihistamine for itch/urticaria ▸ Corticosteroids — minimal evidence for biphasic Px Adjuncts do NOT replace epinephrine ③ Biphasic Observation Tiers Mild + single epi + rapid response: Observe 4–6 hours Severe / ≥ 2 epi doses / hypotension: Observe 6–12 hours (or admit) Refractory / intubation / pressor: PICU admission, 24-h obs minimum Biphasic incidence: ▸ ~5–10% pediatric (range 0–20% in literature) ▸ Median onset ~10 h; up to 72 h tail ④ LEAP / EAT — Early Introduction Era Peanut: 4–11 mo for high-risk infants LEAP: 80% relative risk reduction at age 5 High-risk = ANY of: ▸ Severe eczema ▸ Egg allergy ▸ Both → highest risk → introduce by 4–6 mo Skin prick first if severe risk: ▸ < 3 mm: home introduction safe ▸ 3–7 mm: supervised in-clinic challenge ▸ > 7 mm: avoid + ongoing surveillance “Delay to age 3” is OBSOLETE — actively harmful

1. Epinephrine First, Adjuncts Second

The single most common preventable bad outcome in pediatric anaphylaxis seasoned clinicians see is the antihistamine-first or “let’s see if it gets worse” reflex. In experienced practice the threshold to give intramuscular epinephrine is the presence of any two body-system involvement — skin plus respiratory, respiratory plus cardiovascular, or any known allergen exposure with hypotension or airway involvement — without waiting for the full diagnostic certainty. Diphenhydramine is an adjunct for itch and urticaria, not a treatment for anaphylaxis. Experienced practitioners would rather give a dose of epinephrine to a child whose final diagnosis turns out to be severe urticaria than withhold it from one whose anaphylaxis progresses while they temporize.

2. Vastus Lateralis, Not Deltoid — and Not Subcutaneous

The under-recognized administration error is the deltoid intramuscular shot or the older subcutaneous route. In practice the mid-anterolateral thigh (vastus lateralis muscle) is the site of every IM epinephrine dose, and experienced clinicians teach it explicitly to school nurses and parents at every auto-injector visit. The vastus has the highest perfusion among accessible IM sites and the fastest peak serum epinephrine; the deltoid is meaningfully slower and the subcutaneous route is the slowest of all. Auto-injectors are designed to be activated through clothing, and field administration should never be delayed for clothing removal.

3. The Second Dose Threshold Is Real

Roughly 40% of pediatric anaphylaxis cases need at least two doses of epinephrine — a number clinicians have learned to internalize and pre-empt rather than be surprised by. In practice if there is any persistent or worsening respiratory symptom, any continued hypotension after intravenous fluid bolus, or any progression toward cardiovascular collapse at the 5- to 15-minute reassessment, the second IM dose is given without further deliberation. The single-dose mindset is, in experienced hands, the most common contributor to bad outcomes in this disease.

4. Introduce Peanut Early in High-Risk Infants — LEAP Reshaped This

The LEAP trial reshaped allergy prevention so dramatically that the “delay introduction to age 3” guidance seasoned clinicians trained under is now actively harmful. In experienced practice every infant with severe eczema or established egg allergy receives a structured peanut-introduction conversation at the 4- to 6-month well-child visit; the highest-risk subgroup (both eczema and egg allergy) earns a skin prick test, and home introduction is offered if the wheal is under 3 mm, supervised in-clinic challenge if 3–7 mm, and avoidance plus ongoing surveillance if greater than 7 mm. The EAT trial extended this paradigm to other allergens, and the 80% relative risk reduction in peanut allergy at age 5 in the LEAP early-introduction arm is one of the largest preventable-disease effects experienced practitioners get to deliver in primary care.

Illustrative Scenario

A four-year-old patient with known peanut allergy and prior anaphylactic episode accidentally ingested a peanut-containing dessert at a birthday party. Within ten minutes the child developed generalized urticaria, facial and periorbital swelling, audible inspiratory stridor, and tachycardia with a measured systolic blood pressure that read low for age. The school nurse on scene administered the child’s prescribed EpiPen Jr (0.15 mg) intramuscularly to the mid-anterolateral thigh through clothing within four minutes of symptom onset and activated emergency medical services.

On ED arrival the child remained tachycardic and had a borderline blood pressure with persistent mild stridor. A second IM epinephrine dose (0.15 mg) was given at the 12-minute mark from initial dose, intravenous normal saline 20 mL/kg was infused, nebulized albuterol was added for residual wheeze, and intravenous methylprednisolone was given for ongoing urticaria. Symptoms resolved over the next 90 minutes. Given the severe initial presentation with two epinephrine doses, the patient was observed for 8 hours without biphasic recurrence. Discharge medications included two auto-injectors (one for home, one for school), a written anaphylaxis action plan, antihistamine for residual urticaria, and an outpatient pediatric allergy referral for component-resolved diagnostics and discussion of oral immunotherapy candidacy.

Takeaway: Rapid school-based IM epinephrine plus protocol-driven second-dose escalation plus a discharge package with two auto-injectors and a written action plan converts a potentially catastrophic event into a structured recovery. The decisive moment was the school nurse’s four-minute response.

Standing Protocol Adjustments

  1. Give IM epinephrine to the mid-anterolateral thigh (vastus lateralis) on any two-body-system anaphylaxis or known-allergen exposure with airway or hypotension — never deltoid, never subcutaneous, never wait for diphenhydramine to work.
  2. Weight-based dosing: 0.15 mg for 7.5–25 kg (0.1 mg for 7.5 to <15 kg where available), 0.3 mg for > 25 kg, and 0.01 mg/kg drawn up from 1 mg/mL below 7.5 kg; through clothing if needed; document site and time of every dose.
  3. Anticipate the second dose at 5–15 minutes if any persistent or worsening respiratory or cardiovascular feature; pair with IV fluid 20 mL/kg boluses; remember adjuncts (antihistamines, steroids, β-agonists) do not replace epinephrine.
  4. Discharge every anaphylaxis patient with two auto-injectors, a written action plan, antihistamine for residual urticaria, and an allergy referral; for high-risk infants (severe eczema, egg allergy), have the LEAP-aligned early peanut introduction conversation at the 4- to 6-month well-child visit.

Leave a Reply

Your email address will not be published. Required fields are marked *